(Q24245969)

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Successful recruitment of minorities into clinical trials: The Kick It at Swope project

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Predictors of smoking cessation among African-Americans enrolled in a randomized controlled trial of bupropion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Does menthol attenuate the effect of bupropion among African American smokers?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers*

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Effects of past history of major depression on smoking characteristics, monoamine oxidase-A and -B activities and withdrawal symptoms in dependent smokers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

The effects of fluoxetine combined with nicotine inhalers in smoking cessation--a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Gender differences in smoking cessation in a placebo-controlled trial of bupropion with behavioral counseling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Mediating mechanisms for the impact of bupropion in smoking cessation treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Pharmacogenetic investigation of smoking cessation treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

A randomized trial of sertraline as a cessation aid for smokers with a history of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

A multicenter, randomized, double-blind, placebo-controlled, 6-month trial of bupropion hydrochloride sustained-release tablets as an aid to smoking cessation in hospital employees

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

A placebo controlled trial of bupropion for smoking cessation in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Nortriptyline and cognitive-behavioral therapy in the treatment of cigarette smoking.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Psychological intervention and antidepressant treatment in smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

The effect of bupropion sustained-release on cigarette craving after smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Effects of gender on relapse prevention in smokers treated with bupropion SR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. a randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Bupropion for pharmacologic relapse prevention to smoking: predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic posttraumatic stress disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Bupropion for smoking cessation : predictors of successful outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Late-term smoking cessation despite initial failure: an evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Targeting smokers at increased risk for relapse: treating women and those with a history of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Onset of major depression during treatment for nicotine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Nicotine patch and paroxetine for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Experimenter-defined quit dates for smoking cessation: adherence improves outcomes for women but not for men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Influence of fluoxetine on positive and negative affect in a clinic-based smoking cessation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

A randomized trial of nortriptyline for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Bupropion SR and smoking cessation in actual practice: methods for recruitment, screening, and exclusion for a field trial in a managed-care setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Bupropion SR and counseling for smoking cessation in actual practice: predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Heterogeneity in 12-month outcome among female and male smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Effectiveness of bupropion sustained release for smoking cessation in a health care setting: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

A multicentre, randomized, double-blind, placebo-controlled, 1-year study of bupropion SR for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Lazabemide, a selective, reversible monoamine oxidase B inhibitor, as an aid to smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

A randomized controlled trial of oral selegiline plus nicotine skin patch compared with placebo plus nicotine skin patch for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Tryptophan and high-carbohydrate diets as adjuncts to smoking cessation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Bupropion for the treatment of nicotine dependence in spit tobacco users: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Doxepin as an adjunct to smoking cessation: a double-blind pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Effects of doxepin on withdrawal symptoms in smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

A preliminary placebo-controlled trial of selegiline hydrochloride for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Effects of selegiline (L-deprenyl) during smoking and short-term abstinence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Nicotine reduction and bupropion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Effects of fluoxetine on weight gain and food intake in smokers who reduce nicotine intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

The effect of bupropion on nicotine craving and withdrawal.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Bupropion exposures: clinical manifestations and medical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Evaluation of the safety of bupropion (Zyban) for smoking cessation from experience gained in general practice use in England in 2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Antidepressants and smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Statistical analysis of randomized trials in tobacco treatment: longitudinal designs with dichotomous outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Effect of nonnicotine pharmacotherapy on smoking behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Treatment of nicotine dependence with bupropion SR: review of its efficacy, safety and pharmacological profile.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Review of bupropion for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Nicotine replacement therapy for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Zyban-- is there a cause for concern?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Smoking cessation guidelines for health professionals: an update. Health Education Authority

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Bupropion SR for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Nicotine and bupropion share a similar discriminative stimulus effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Beta blockade during and after myocardial infarction: an overview of the randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Tolerability and safety of sustained-release bupropion in the management of smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Clinical efficacy of bupropion in the management of smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Use of sustained-release bupropion in specific patient populations for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

Buspirone reduces smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

7 January 2021

Cost-benefit analysis of sustained-release bupropion, nicotine patch, or both for smoking cessation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

7 January 2021

Weight suppression and weight rebound in ex-smokers treated with fluoxetine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

7 January 2021

Antidepressant pharmacotherapy helps some cigarette smokers more than others

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

7 January 2021

Influences of gender and weight gain on short-term relapse to smoking in a cessation trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

7 January 2021

Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

7 January 2021

Nicotine-like discriminative stimulus effects of bupropion in rats

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

7 January 2021

Influence of antidepressant pharmacotherapy on behavioral treatment adherence and smoking cessation outcome in a combined treatment involving fluoxetine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

7 January 2021

A comparison of sustained-release bupropion and placebo for smoking cessation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

7 January 2021

Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

7 January 2021

Controlled Trial for Smoking Cessation in a Navy Shipboard Population Using Nicotine Patch, Sustained-Release Buproprion, or Both

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

7 January 2021

Fluoxetine versus placebo to decrease the smoking of depressed alcoholic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

7 January 2021

Interaction of Personality and Treatment Conditions Associated with Success in a Smoking Control Program

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

7 January 2021

Mood, major depression, and fluoxetine response in cigarette smokers

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

7 January 2021

Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

7 January 2021

Nicotine reduction: effectiveness of bupropion

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

7 January 2021

Stopping smoking: a prospective, randomized, double-blind study comparing nortriptyline to placebo

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

7 January 2021

A prospective safety surveillance study for bupropion sustained-release in the treatment of depression.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

7 January 2021

Bupropion: pharmacological and clinical profile in smoking cessation.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

7 January 2021

A comparison of sustained-release bupropion and placebo for smokeless tobacco cessation.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD000031.PUB2

7 January 2021

10.1002/14651858.CD000031.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

4440599

OpenCitations bibliographic resource ID

4440599

1 reference